87 related articles for article (PubMed ID: 28647053)
1. Resistance to hepatitis C virus. Implications and therapeutic options.
Llerena S; Cabezas J; Iruzubieta P; Crespo J
Gastroenterol Hepatol; 2017; 40(7):484-494. PubMed ID: 28647053
[TBL] [Abstract][Full Text] [Related]
2. Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
Susser S; Flinders M; Reesink HW; Zeuzem S; Lawyer G; Ghys A; Van Eygen V; Witek J; De Meyer S; Sarrazin C
Antimicrob Agents Chemother; 2015 May; 59(5):2746-55. PubMed ID: 25712364
[TBL] [Abstract][Full Text] [Related]
3. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
Giménez-Manzorro Á; García-González X; Rodríguez-González CG; Ochoa-Palominos A; Sanjurjo-Sáez M; Clemente-Ricote G
Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
[TBL] [Abstract][Full Text] [Related]
5. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.
Premoli C; Aghemo A
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):76-87. PubMed ID: 26448306
[TBL] [Abstract][Full Text] [Related]
6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
7. [Future prospects for hepatitis C treatment: without interferon and ribavirin?].
Lens S; Alfaro I
Gastroenterol Hepatol; 2014 May; 37(5):311-21. PubMed ID: 24679376
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus resistance to the new direct-acting antivirals.
Esposito I; Trinks J; Soriano V
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
[TBL] [Abstract][Full Text] [Related]
9. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
10. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
[TBL] [Abstract][Full Text] [Related]
12. The hepatitis C revolution part 1: antiviral treatment options.
Thiagarajan P; Ryder SD
Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
[TBL] [Abstract][Full Text] [Related]
13. [Retreatment of chronic hepatitis C patients non responder to a previous antiviral treatment].
Taliani G; Biliotti E
Recenti Prog Med; 2007 Apr; 98(4):219-24. PubMed ID: 17547358
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
Coppola N; Pisaturo M; Zampino R; Macera M; Sagnelli C; Sagnelli E
World J Gastroenterol; 2015 Oct; 21(38):10749-59. PubMed ID: 26478667
[TBL] [Abstract][Full Text] [Related]
15. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
16. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.
Florian J; Mishra P; Arya V; Harrington P; Connelly S; Reynolds KS; Sinha V
Clin Pharmacol Ther; 2015 Oct; 98(4):394-402. PubMed ID: 26179495
[TBL] [Abstract][Full Text] [Related]
17. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.
Ismail AM; Sharma OP; Kumar MS; Eapen CE; Kannangai R; Abraham P
Antiviral Res; 2013 May; 98(2):209-16. PubMed ID: 23485939
[TBL] [Abstract][Full Text] [Related]
18. Telbivudine in the treatment of chronic hepatitis B.
Nash K
Adv Ther; 2009 Feb; 26(2):155-69. PubMed ID: 19225726
[TBL] [Abstract][Full Text] [Related]
19. [Retreatment options for patients with chronic hepatitis C].
Hrstić I; Ostojić R; Vucelić B
Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
